MARKET

SIOX

SIOX

Sio Gene Therapies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.890
+0.250
+9.47%
After Hours: 2.850 -0.04 -1.38% 18:16 03/01 EST
OPEN
2.760
PREV CLOSE
2.640
HIGH
3.090
LOW
2.710
VOLUME
5.65M
TURNOVER
--
52 WEEK HIGH
5.74
52 WEEK LOW
1.410
MARKET CAP
169.79M
P/E (TTM)
-2.5115
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
5 Penny Stock To Watch In March 2021 With Potential Biotech Catalysts
Feb 28, 2021 (Penny Stocks via COMTEX) -- Biotech Penny Stocks To Watch Right Now February closed out with a tumultuous week of trading in more than just...
Penny Stocks · 1d ago
NIU, SPPI, BDSI and SVC among after-hours movers
Gainers: [[SIOX]] +12.1%. [[OPTN]] +7.2%. [[BDSI]] +5.7%. [[SSP]] +4.9%. [[SPPI]] +4.9%.Losers: [[PCTI]] -6.5%. [[SVC]] -5.4%. [[GNFT]] -4.2%. [[NIU]] -3.4% [[CATB]] -2%.
Seekingalpha · 3d ago
Roivant to buy Silicon Therapeutics for $450 mln to boost drug discovery
reuters.com · 3d ago
Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present at the 10 Annual SVB Leerink Glo...
GlobeNewswire · 02/16 12:00
Sio Gene Therapies (SIOX) Receives a Hold from Oppenheimer
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Sio Gene Therapies (SIOX). The company's shares closed last Thursday at
SmarterAnalyst · 02/11 22:25
10-Q: SIO GENE THERAPIES INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 02/09 14:43
BRIEF-Sio Gene Therapies Posts Q3 Loss Per Share $0.20
reuters.com · 02/09 12:13
Sio Gene Therapies EPS beats by $0.09
Sio Gene Therapies (SIOX): FQ3 GAAP EPS of -$0.20 beats by $0.09.cash and cash equivalents of $81M.Press Release
Seekingalpha · 02/09 12:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SIOX. Analyze the recent business situations of Sio Gene Therapies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SIOX stock price target is 8.88 with a high estimate of 12.50 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 94
Institutional Holdings: 14.29M
% Owned: 24.33%
Shares Outstanding: 58.75M
TypeInstitutionsShares
Increased
16
3.21M
New
42
-31.00K
Decreased
8
303.12K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.14%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
Chairman/Director
Frank Torti
Chief Executive Officer/Director
Pavan Cheruvu
Chief Financial Officer/Chief Accounting Officer/General Counsel
David Nassif
Other
Gavin Corcoran
Other
Parag Meswani
Lead Director/Independent Director
Atul Pande
Director
Eric Venker
Director
Kristiina Vuori
Independent Director
Berndt Modig
Independent Director
Senthil Sundaram
  • Dividends
  • Splits
  • Insider Activity
No Data
About SIOX
Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc, Axovant Sciences GmbH, Axovant Sciences Amercia, Inc., Axovant Treasury Holdings, Inc., Axovant Treasury, Inc and Axovant Sciences Europe Ltd. The Company’s clinical-stage programs include AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2 program.

Webull offers kinds of Sio Gene Therapies Inc stock information, including NASDAQ:SIOX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIOX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SIOX stock methods without spending real money on the virtual paper trading platform.